Autologous tumor-associated antigens presented by patient dendritic cells (TAA-DC)

Autologous tumor-associated antigens presented by patient dendritic cells represent a personalized immunotherapy approach where a patient's own immune system is trained to recognize specific cancer markers. Dendritic cells, the most potent antigen-presenting cells, are loaded ex vivo with antigens derived from the patient's own tumor tissue, ensuring the immune response is tailored to the unique mutational profile of that individual's malignancy (Banchereau & Steinman, Nature 1998). Once re-infused, these mature dendritic cells present the antigens via Major Histocompatibility Complex (MHC) molecules to naive T-cells in the lymph nodes. This process triggers the expansion of tumor-specific cytotoxic T lymphocytes and helper T-cells, which then circulate and infiltrate the tumor microenvironment to execute targeted cell killing (Kantoff et al., NEJM 2010). This strategy aims to overcome the immune evasion mechanisms employed by tumors and provide long-lasting immunological memory. Clinical applications include vaccines for glioblastoma, prostate cancer, and melanoma, with Sipuleucel-T being a landmark approved therapy in this class (Liau et al., JAMA Oncology 2023). The complexity of manufacturing and the need for fresh tumor tissue remain significant hurdles for widespread adoption. Despite these challenges, the approach offers a high degree of specificity and a favorable safety profile compared to traditional chemotherapy.

Other names

Autologous tumor antigensPatient-specific tumor-associated antigensDC-presented tumor antigensAutologous tumor lysateAutologous dendritic cell vaccine

Dendritic cell-mediated activation of tumor-specific T-cells via presentation of autologous tumor-associated antigens.